[Laboratory diagnostic with regard to new anticoagulants - monitoring and influence on coagulation tests]

Nagler, M; Wuillemin, W (2012). [Laboratory diagnostic with regard to new anticoagulants - monitoring and influence on coagulation tests]. Therapeutische Umschau, 69(11), pp. 650-6. Bern: Huber 10.1024/0040-5930/a000343

Full text not available from this repository. (Request a copy)

New oral anticoagulants promise to overcome essential drawbacks of traditional substances. They have a predictable therapeutic effect, a wide therapeutic window, only limited interaction with food and drugs and can be administered p.o. with a fixed dose. On the other hand, knowledge on the laboratory management of new anticoagulants is limited. In the present article we discuss possible indications and available assays for monitoring of Rivaroxaban, Apixaban and Dabigatran. Furthermore, we discuss interpretation of routine coagulation tests during therapy with these new drugs.

Item Type:

Journal Article (Further Contribution)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Haematology and Central Haematological Laboratory

UniBE Contributor:

Nagler, Michael

ISSN:

0040-5930

Publisher:

Huber

Language:

German

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:32

Last Modified:

17 Mar 2015 21:20

Publisher DOI:

10.1024/0040-5930/a000343

PubMed ID:

23117668

URI:

https://boris.unibe.ch/id/eprint/12591 (FactScience: 218953)

Actions (login required)

Edit item Edit item
Provide Feedback